| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Halladay Benjamin is a Chief Financial Officer at Esperion Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 9 sells.
Estimated insider holdings value: $1.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 7,337 | $3.67 | $26,904.78 | -1.5% | -25.8% | - | |
| Sep 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 7,046 | $2.81 | $19,785.17 | -1.5% | +36.4% | - | |
| Jul 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 11 | $1.12 | $12.27 | - | +103.2% | - | |
| Jun 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 7,229 | $1.15 | $8,327.81 | -1.5% | +155.0% | - | |
| Apr 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 8 | $0.96 | $7.71 | - | +17.9% | - | |
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 3,535 | $1.48 | $5,242.41 | -0.7% | -25.9% | +58.9% | |
| Feb 19, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 11 | $1.86 | $20.46 | - | -52.2% | +85.3% | |
| Jan 17, 2025 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 9 | $2.27 | $20.39 | - | -57.0% | +37.6% | |
| Dec 17, 2024 | ESPR Esperion Therapeutics, Inc. | Chief Financial Officer | Sell | 3,245 | $2.42 | $7,865.88 | -1.3% | -37.4% | +48.4% |